Effective Single Dose Treatment of Uncomplicated Gonorrhoea

Avonts D Fransen L Vielfont J Stevens A Hendricks K. Treating uncomplicated gonococcal infection with 250 mg or 100 mg ciprofloxacin in a single oral dose. Genitourin Med 1988;64:134.

Aznar J Prados R Rodriquez-Pichardo A Hernandez I De Miguel C Perea EJ. Comparative clinical efficacy of two different single-dose ciprofloxacin treatments of uncomplicated gonorrhea. Sex Transm Dis 1986;13:168–71.

Bryan JP Hira SK Brady W Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia. Antimicrob Agents Chemother 1990;34:819–22.

Backhaus A Rohn J. Meyer The treatment of gonococcal urethritis with cefotaxime. J Antimicrob Chemother 1980;6(suppl A):291.

Beam TR Jr. Ceftriaxone: A β-lactamase stable, broadspectrum cephalosporin with an extended half-life. Pharmacotherapy 1985;5:237–53.

Boslero JW Tramont EC Takafuji E Effect of spectinomycin use on the prevalence of spectinomycin resistant and of penicillinase-producing Neisseria gonorrhoeae . N Engl J Med 1987;317:272–8.

Canadian Medical Association: Guidelines for the treatment of gonorrhea. Can Med Assoc J 1992;146:1587–8.

Centers for Disease Control: 1989 Sexually transmitted disease guidelines. MMWR 1989;28:1–43.

Centers for Disease Control: Tetracycline resistant Neisseria gonorrhoeae: Georgia, Pennsylvania, New Hampshire. MMWR 1985;34:304–11.

Centers for Disease Control: Spectinomycin resistant Neisseria gonorrhoeae—worldwide. MMWR 1982;31:632–8.

Dixon CA Bittiner JB Shahidulla M Slack RCB Salaiman MCZ. Randomised observer blind competitive trial of ceftriaxone and penicillin in treating uncomplicated gonorrhea in men and women. Genitourin Med 1986;62:78–81.

Fraschini F Braga PC Scarpazza G Human pharmacokinetics and distribution in various tissues of ceftriaxone. Chemotherapy 1986;32:192–9.

Hard S Moberg I Wennberg K. Treatment of gonococcal urethritis in males with single dose of cefotaxime. J Antimicrob Chemother 1980;6(suppl A):289.

Handsfield HH Holmes KK. Treatment of uncomplicated gonorrhea with single dose of cefotaxime. Sex Transm Dis 1981;8:187–91.

Handsfield HH McCormack WM Hook EW A comparison of single dose Cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. N Engl J Med 1991;325:1337–41.

Hook EW Roddy RE Handsfield HH. Ceftriaxone therapy for incubating syphilis. J Infect Dis 1988;158:881–4.

de Hoop D Nayyar KC van Klingeren B Stolz E Michel MF. Infections with non penicillinase-producing strains of Neisseria gonorrhoeae treated with cefuroxime: treatment failures. Sex Transm Dis 1982;9:200–1.

Jaffé HW. Infections due to penicillinase producing Neisseria gonorrhoeae in the United States: 1976–1978. J Infect Dis 1981;144:191–7.

Karney WW Turk M Holmes KK. Cefazolin in the treatment of gonorrhea. J Infect Dis 1973;128(suppl):399–403.

Kerbs SB Stone JR Jr Berg SW Harrison WO. In vitro antimicrobial activity of eight new β-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae . Antimicrob Agents Chemother 1982;22:541–4.

Van Klingeren W Van Wijngaaden LJ Dessens-Kroon M van Embden JDH. Penicillinase producing gonococci in the Netherlands in 1981. J Antimicrob Chemother 1983;11:15–20.

Knapp JS Zenilman JM Biddle JW Frequency and distribution in the United States of strains of Neisseria gonorrhoeae with plasmid mediated, high level resistance to tetracycline. J Infect Dis 1987;155:819–22.

Korting HC Abeck D. One shot treatment of uncomplicated gonorrhea with third generation cephalosporins with differing serum half-life. Chemotherapy 1989;35:441–8.

Korting HC Walther D Riethmüller U Meurer M. Comparative in vitro susceptibility of Treponema pallidum to ceftixozime, ceftriaxone and penicillin G. Chemotherapy 1986;32:352–5.

Korting HC Abeck D Zaba R. Increase of the frequency of penicillinase-producing Neisseria gonorrhoeae strains to more than five percent in Munich. Zbl Bakteriol 1990;272:313–17.

Kuhlwein A Nies BA. Efficacy and safety of a single 400 mg dose of Cefixime in the treatment of uncomplicated gonorrhea. Eur J Clin Microbiol Infect Dis 1989;8:261–2.

Le Saux N Ronald AR. Role of ceftriaxone in sexually transmitted diseases. Rev Infect Dis 1989;11:299–309.

Lucas JB Thayer JD Utley PM Billings TE Hackney JF. Treatment of gonorrhea in males with cephaloridine. JAMA 1966;195:919–21.

Lucas JB Thayer JD Utley PM Billings TE Hackney JF. Cephalothin therapy in male gonorrhea. Antimicrob Agents Chemother 1965;3:686–8.

McCutchan JA Adler MW Berrie JHR. Penicillinase-producing Neisseria gonorrheae in Great Britain, 1977–81: Alarming increase in incidence and recent development of endemic transmission. BMJ 1982;285:337–40.

Megran DW Lefebre K Willets V Bowie WR. Single dose oral Cefixime versus amoxicillin plus probenicid for the treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1990;34:355–7.

Moskowitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984;77(suppl 4c):84–8.

Nakata K Maeda H Fuji A Arakawa S Umezu K Kamidono S. In vitro and in vivo activities of Sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis . Antimicrob Agents Chemother 1992;36:188–91.

Nelson M. Cefazolin in the treatment of uncomplicated gonorrhea in men. J Infect Dis 1973;128(suppl):44–6.

Neu HC Meropol NJ Fu KP. Antibacterial activity of ceftriaxone (Ro 13–9904), a β-lactamase-stable cephalosporin. Antimicrob Agents Chemother 1981;19:423–41.

Neubert U Korting HC Ruckdeschel G. Susceptibility of Neisseria gonorrhoeae to cefotaxime: in vitro studies and treatment results. Arch Dermatol Res 1982;274:321–6.

Plourde PJ Tyndall M Agoki ER Single dose Cefixime versus single dose ceftriaxone in the treatment of antimicrobial resistant Neisseria gonorrhoeae infection. J Infect Dis 1992;166:919–22.

Rajakuma MK Ngeow YF Khor BS Lim KF. Ofloxacin, a new quinolone in the treatment of gonorrhea. Sex Transm Dis 1988;15:25–6.

Rice RJ Thompson SE. Treatment of uncomplicated infections due to Neisseria gonorrhoeae: a review of clinical efficacy and in vitro susceptibility studies from 1982 through 1985. JAMA 1986;255:1739–46.

Roddy RE Handsfield HH Hook EW. Comparative trial of single dose ciprofloxacin and ampicillin plus probenecid for the treatment of gonococcal urethritis in men. Antimicrob Agents Chemother 1986;30:267–9.

Stoeckl K. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long serum half-life. Chemotherapy 1981;27(suppl 1):42–6.

Stone JW Linong G Andrews JW Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother 1989;23:221–2.

WHO Scientific Group: Neisseria gonorrhoeae and gonococcal infections. World Health Organization Technical Report Series 616, World Health Organization, Geneva, 1978:91–104.

van der Willigen AH Degener JE Vogel M Stolz E Wagenvoort JHT. In vitro activities of seven quinolone derivatives against Neisseria gonorrhoeae . Arzneim Forsch 1990;40:684–5.

Wise R Baker S Livingstone R. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother 1980;18:369–71.

Wolfson JS Hooper DC. Treatment of genitourinary tract infections with fluoroquinolones: Activity in vitro, pharmacokinetics and clinical efficacy on urinary tract infections and prostatitis. Antimicrob Agents Chemother 1989;33:1655–61.

Zishka PA Douglas JM Jr. Immediate hypersensitivity reaction to single dose parenteral ceftriaxone therapy for gonorrhea. Sex Transm Dis 1991;19:26–7.